<p>Nanobiotix S.A. - 赞助的 ADR (NASDAQ:NBTX - 获取免费报告) 在四月份经历了大幅减少的空头头寸。截至四月十五日，空头头寸总计为 11,234 股，较三月三十一日的 25,474 股减少了 55.9%。该股票约有 0.0% 的股份被卖空。根据平均交易量 71,965 股，目前的覆盖天数比率为 0.2 天。</p>
<h2>Nanobiotix 股票下跌 0.4%</h2>
<p>Nanobiotix 股票在周五下跌了 0.13 美元，达到 33.58 美元。该公司的股票交易量为 58,364 股，而其平均交易量为 67,082 股。Nanobiotix 的 52 周低点为 3.13 美元，52 周高点为 41.89 美元。该股票的 50 日移动平均价格为 31.12 美元，200 日移动平均价格为 25.12 美元。</p>
<p>Nanobiotix (NASDAQ:NBTX - 获取免费报告) 最近在二月十五日发布了季度财报。公司报告该季度每股收益为（0.23）美元。该季度的收入为 342 万美元。分析师预计，Nanobiotix 在当前财年将发布 0.53 美元的每股收益。</p>
<h2>Nanobiotix 的机构交易</h2>
<p>几家大型投资者最近对 NBTX 的持仓进行了调整。加拿大皇家银行在第四季度将其在 Nanobiotix 的持仓增加了 2000.0%。加拿大皇家银行目前拥有 2,625 股该公司的股票，价值 61,000 美元，此前在上个季度购买了额外的 2,500 股。Optiver Holding B.V. 在第三季度获得了 Nanobiotix 的新头寸，价值 101,000 美元。Marshall Wace LLP 在第四季度购买了 Nanobiotix 的新股份，价值 220,000 美元。最后，Millennium Management LLC 在第四季度购买了 Nanobiotix 的新股份，价值 390,000 美元。目前 38.81% 的股票由对冲基金和其他机构投资者持有。</p>
<h2>华尔街分析师观点</h2>
<p>NBTX 最近成为多份分析师报告的主题。Guggenheim 将 Nanobiotix 的目标价格从 26.00 美元上调至 36.00 美元，并在四月二日的研究报告中给予该股票 “买入” 评级。TD Cowen 在三月十二日的研究报告中重申了对 Nanobiotix 股票的 “买入” 评级。最后，Weiss Ratings 在周二的研究报告中重申了对 Nanobiotix 股票的 “卖出（d-）” 评级。四位分析师对该股票给予了买入评级，一位分析师给予了卖出评级。根据 MarketBeat 的数据，该股票目前的平均评级为 “适度买入”，共识目标价格为 25.00 美元。</p>
<p><strong>阅读我们关于 NBTX 的最新报告</strong></p>
<h2>Nanobiotix 公司简介</h2>
<p>(获取免费报告)</p>
<p>Nanobiotix 是一家总部位于法国巴黎的临床阶段生物技术公司，专注于开发新型纳米药物以改善癌症治疗。公司的主打产品 NBTXR3 是一种首创的放射增强剂，由铪氧化物纳米颗粒组成，旨在增强放疗对肿瘤细胞的效果，同时保护周围的健康组织。Nanobiotix 在多个癌症适应症上建立了临床项目，包括软组织肉瘤、头颈癌和肝细胞癌。</p>
<p>自成立以来，Nanobiotix 已通过关键试验推进 NBTXR3，并获得了在欧洲治疗软组织肉瘤的 CE 标志批准。</p>
<h2>精选故事</h2>
<ul>
<li>五只我们更看好的股票，而不是 Nanobiotix</li>
</ul>
<p><em>此即时新闻提醒由叙事科学技术和来自 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1,000 美元在 Nanobiotix 吗？</h2>
<p>在你考虑 Nanobiotix 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师正在悄悄向客户推荐的股票，以便在更广泛的市场注意到之前购买...而 Nanobiotix 并不在名单上。</p>
<p>虽然 Nanobiotix 目前在分析师中获得了适度买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>查看这五只股票</p>

NBTX

纳斯达克生物科技指数 ETF - iShares Nasdaq

标普生物技术 3 倍做多 - Direxion

动态生物技术与基因组 ETF - Invesco

标普生物技术 ETF - SPDR

医药突破 ETF - ALPS

纽交所高增长板生物技术指数 ETF - First Trust

2 倍做多纳斯达克生物技术 ETF - ProShares

生物科技 ETF - VanEck Vectors

基因改革 ETF - ARK

<p>Nanobiotix S.A.（纳斯达克代码：NBTX）在空头头寸方面经历了显著下降，截至 4 月 15 日，下降了 55.9%，降至 11,234 股。目前，0.0% 的股份被做空，基于每日平均交易量 71,965 股，覆盖天数比率为 0.2 天。该股票下跌 0.4%，报 33.58 美元，52 周范围为 3.13 美元至 41.89 美元。分析师维持 “适度买入” 评级，普遍目标价为 25.00 美元。该公司专注于开发用于癌症治疗的纳米药物，特别是其主打产品 NBTXR3</p>

<p>Nanobiotix S.A. - Sponsored ADR (NASDAQ:NBTX - Get Free Report) was the recipient of a large decrease in short interest during the month of April. As of April 15th, there was short interest totaling 11,234 shares, a decrease of 55.9% from the March 31st total of 25,474 shares. Approximately 0.0% of the shares of the stock are sold short. Based on an average trading volume of 71,965 shares, the days-to-cover ratio is presently 0.2 days.</p>
<div class="lb-trans"><p>Nanobiotix S.A. - 赞助的 ADR (NASDAQ:NBTX - 获取免费报告) 在四月份经历了大幅减少的空头头寸。截至四月十五日，空头头寸总计为 11,234 股，较三月三十一日的 25,474 股减少了 55.9%。该股票约有 0.0% 的股份被卖空。根据平均交易量 71,965 股，目前的覆盖天数比率为 0.2 天。</p>
</div><h2>Nanobiotix Stock Down 0.4%</h2>
<div class="lb-trans"><h2>Nanobiotix 股票下跌 0.4%</h2>
</div><p>Shares of Nanobiotix stock traded down $0.13 on Friday, reaching $33.58. The company's stock had a trading volume of 58,364 shares, compared to its average volume of 67,082. Nanobiotix has a 52-week low of $3.13 and a 52-week high of $41.89. The stock has a 50-day moving average price of $31.12 and a 200-day moving average price of $25.12.</p>
<div class="lb-trans"><p>Nanobiotix 股票在周五下跌了 0.13 美元，达到 33.58 美元。该公司的股票交易量为 58,364 股，而其平均交易量为 67,082 股。Nanobiotix 的 52 周低点为 3.13 美元，52 周高点为 41.89 美元。该股票的 50 日移动平均价格为 31.12 美元，200 日移动平均价格为 25.12 美元。</p>
</div><p>Nanobiotix (NASDAQ:NBTX - Get Free Report) last issued its quarterly earnings results on Sunday, February 15th. The company reported ($0.23) EPS for the quarter. The company had revenue of $3.42 million during the quarter. On average, analysts anticipate that Nanobiotix will post 0.53 EPS for the current fiscal year.</p>
<div class="lb-trans"><p>Nanobiotix (NASDAQ:NBTX - 获取免费报告) 最近在二月十五日发布了季度财报。公司报告该季度每股收益为（0.23）美元。该季度的收入为 342 万美元。分析师预计，Nanobiotix 在当前财年将发布 0.53 美元的每股收益。</p>
</div><h2>Institutional Trading of Nanobiotix</h2>
<div class="lb-trans"><h2>Nanobiotix 的机构交易</h2>
</div><p>Several large investors have recently made changes to their positions in NBTX. Royal Bank of Canada increased its position in shares of Nanobiotix by 2,000.0% during the fourth quarter. Royal Bank of Canada now owns 2,625 shares of the company's stock worth $61,000 after purchasing an additional 2,500 shares in the last quarter. Optiver Holding B.V. acquired a new position in Nanobiotix during the third quarter worth $101,000. Marshall Wace LLP purchased a new stake in Nanobiotix in the 4th quarter valued at $220,000. Finally, Millennium Management LLC purchased a new stake in Nanobiotix in the 4th quarter valued at $390,000. 38.81% of the stock is currently owned by hedge funds and other institutional investors.</p>
<div class="lb-trans"><p>几家大型投资者最近对 NBTX 的持仓进行了调整。加拿大皇家银行在第四季度将其在 Nanobiotix 的持仓增加了 2000.0%。加拿大皇家银行目前拥有 2,625 股该公司的股票，价值 61,000 美元，此前在上个季度购买了额外的 2,500 股。Optiver Holding B.V. 在第三季度获得了 Nanobiotix 的新头寸，价值 101,000 美元。Marshall Wace LLP 在第四季度购买了 Nanobiotix 的新股份，价值 220,000 美元。最后，Millennium Management LLC 在第四季度购买了 Nanobiotix 的新股份，价值 390,000 美元。目前 38.81% 的股票由对冲基金和其他机构投资者持有。</p>
</div><h2>Wall Street Analyst Weigh In</h2>
<div class="lb-trans"><h2>华尔街分析师观点</h2>
</div><p>NBTX has been the topic of a number of recent analyst reports. Guggenheim increased their target price on Nanobiotix from $26.00 to $36.00 and gave the stock a &#34;buy&#34; rating in a research note on Thursday, April 2nd. TD Cowen reiterated a &#34;buy&#34; rating on shares of Nanobiotix in a research note on Thursday, March 12th. Finally, Weiss Ratings reiterated a &#34;sell (d-)&#34; rating on shares of Nanobiotix in a research note on Tuesday. Four analysts have rated the stock with a Buy rating and one has given a Sell rating to the company's stock. According to data from MarketBeat, the stock presently has an average rating of &#34;Moderate Buy&#34; and a consensus price target of $25.00.</p>
<div class="lb-trans"><p>NBTX 最近成为多份分析师报告的主题。Guggenheim 将 Nanobiotix 的目标价格从 26.00 美元上调至 36.00 美元，并在四月二日的研究报告中给予该股票 “买入” 评级。TD Cowen 在三月十二日的研究报告中重申了对 Nanobiotix 股票的 “买入” 评级。最后，Weiss Ratings 在周二的研究报告中重申了对 Nanobiotix 股票的 “卖出（d-）” 评级。四位分析师对该股票给予了买入评级，一位分析师给予了卖出评级。根据 MarketBeat 的数据，该股票目前的平均评级为 “适度买入”，共识目标价格为 25.00 美元。</p>
</div><p><strong>Read Our Latest Report on NBTX</strong></p>
<div class="lb-trans"><p><strong>阅读我们关于 NBTX 的最新报告</strong></p>
</div><h2>Nanobiotix Company Profile</h2>
<div class="lb-trans"><h2>Nanobiotix 公司简介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>(获取免费报告)</p>
</div><p>Nanobiotix is a clinical-stage biotechnology company headquartered in Paris, France, specializing in the development of novel nanopharmaceuticals to improve cancer treatment. The company's lead product, NBTXR3, is a first-in-class radioenhancer composed of hafnium oxide nanoparticles designed to amplify the effect of radiotherapy on tumor cells while sparing surrounding healthy tissue. Nanobiotix has established clinical programs across multiple cancer indications, including soft tissue sarcoma, head and neck cancer, and hepatocellular carcinoma.</p>
<div class="lb-trans"><p>Nanobiotix 是一家总部位于法国巴黎的临床阶段生物技术公司，专注于开发新型纳米药物以改善癌症治疗。公司的主打产品 NBTXR3 是一种首创的放射增强剂，由铪氧化物纳米颗粒组成，旨在增强放疗对肿瘤细胞的效果，同时保护周围的健康组织。Nanobiotix 在多个癌症适应症上建立了临床项目，包括软组织肉瘤、头颈癌和肝细胞癌。</p>
</div><p>Since its inception, Nanobiotix has advanced NBTXR3 through pivotal trials and secured CE Mark approval in Europe for the treatment of soft tissue sarcoma.</p>
<div class="lb-trans"><p>自成立以来，Nanobiotix 已通过关键试验推进 NBTXR3，并获得了在欧洲治疗软组织肉瘤的 CE 标志批准。</p>
</div><h2>Featured Stories</h2>
<div class="lb-trans"><h2>精选故事</h2>
</div><ul>
<li>Five stocks we like better than Nanobiotix</li>
</ul>
<div class="lb-trans"><ul>
<li>五只我们更看好的股票，而不是 Nanobiotix</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和来自 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Nanobiotix Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 Nanobiotix 吗？</h2>
</div><p>Before you consider Nanobiotix, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考虑 Nanobiotix 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Nanobiotix wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师正在悄悄向客户推荐的股票，以便在更广泛的市场注意到之前购买...而 Nanobiotix 并不在名单上。</p>
</div><p>While Nanobiotix currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Nanobiotix 目前在分析师中获得了适度买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>查看这五只股票</p>
</div>

Nanobiotix S.A. - Sponsored ADR (NASDAQ:NBTX) Sees Significant Decline in Short Interest

Market Beat

Nanobiotix SA

加拿大皇家银行

Nanobiotix S.A. - 赞助 ADR（NASDAQ:NBTX）空头头寸显著下降